Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database

This study indicates that ICIs-associated NM/P significantly increases the mortality risk among cancer patients, particularly with the use of nivolumab and pembrolizumab. Strong signals for NM/P were observed with PD-1 inhibitors, pembrolizumab-based regimens, and the combination of nivolumab and ipilimumab. Additionally, a body weight of ≥ 75 kg and the use of nivolumab and ipilimumab may be potential significant risk factors for NM/P.